

PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

Express Mail Label No.

INVENTOR(S)					
Given Name (first and middle [if any])		Family Name or Surname		Residence (City and either State or Foreign Country)	
Daniel Rogers		Burnett		San Francisco, CA 94127	
☐ Additional inventors are being named on the _____ separately numbered sheets attached hereto					
TITLE OF THE INVENTION (500 characters max)					
METHOD AND APPARATUS FOR MAGNETIC INDUCTION THERAPY AND NOTEBOOK PAGES					
Direct all correspondence to: CORRESPONDENCE ADDRESS					
☐ Customer Number				Place Customer Number Bar Code Label here	
OR Type Customer Number here					
☒ Firm or Individual Name	TheraNova, LLC				
Address	215 Valdez Avenue				
Address					
City	San Francisco	State	CA	ZIP	94127
Country	USA	Telephone	(415) 585-8508	Fax	(415) 520-5455
ENCLOSED APPLICATION PARTS (check all that apply)					
☒ Specification	Number of Pages	58	☐ CD(s), Number		
☒ Drawing(s)	Number of Sheets	9	☐ Other (specify)		
☐ Application Data Sheet. See 37 CFR 1.76					
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT					
☒	Applicant claims small entity status. See 37 CFR 1.27.				FILING FEE AMOUNT (\$)
☒	A check or money order is enclosed to cover the filing fees				\$100
☐	The Commissioner is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number:				
☐	Payment by credit card. Form PTO-2038 is attached.				
The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.					
☒ No.					
☐ Yes, the name of the U.S. Government agency and the Government contract number are: _____					

Respectfully submitted,

SIGNATURE

TYPED or PRINTED NAME

TELEPHONE

Daniel Burnett

(415) 585-8508

Date 9 / 30 / 06

REGISTRATION NO.

(if appropriate)

Docket Number:

USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

This collection of information is required by 37 CFR 1.51. The information is used by the public to file (and by the PTO to process) a provisional application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the complete provisional application to the PTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Box Provisional Application Assistant

PATENT APPLICATION

METHOD AND APPARATUS FOR MAGNETIC INDUCTION THERAPY

Inventors: DANIEL R. BURNETT, a citizen of the United States
Residing at 215 Valdez Avenue
San Francisco, California 94127

SHANE MANGRUM, a citizen of the United States
Residing at 5615 Canyonwood Circle
Idaho Falls, Idaho 83406

CHRISTOPHER HERMANSON, a citizen of the United States
Residing at 49 Westdale Drive
Santa Cruz, California 95060

Assignee: THERANOVA, LLC
215 Valdez Avenue
San Francisco, California 94127

Status: Small Entity

THERANOVA, LLC
215 Valdez Avenue
San Francisco, CA 94127
Tel: 415-585-8508
Email: uspto@theranova.net

METHOD AND APPARATUS FOR MAGNETIC INDUCTION THERAPY

[0001] This application claims priority to U.S. Provisional Patent Application Serial No. 60/643,145, filed January 12th, 2005 and is a continuation-in-part of U.S. Pat. No. 6,701,185 entitled "Method and apparatus for electromagnetic stimulation of nerve, muscle, and body tissues" filed February 19th, 2002.

BACKGROUND OF THE INVENTION

[0002] The present invention relates to the field of medical devices, in particular therapeutic intervention devices for central and peripheral nerve modulation therapies, including both excitation and blocking of nerve impulses. Of particular interest is the treatment and prevention of urinary incontinence (UI) and overactive bladder (OAB) with the use of Low Frequency Induction Therapy (LoFIT).

[0003] The OAB and UI market in the United States is well over a \$12 billion a year industry. It affects over 16% of all Americans, for a total U.S. market of approximately 34 million men and women each year. Due to social stigmas attached to OAB and UI, as well as misunderstanding of the signs and symptoms associated with OAB and UI, only 40% of those affected (13.6M) seek treatment. Of those 13.6 million individuals, nearly 30% are unsatisfied with their current therapy.

[0004] The use of pulsed electromagnetic stimulation (PES) has been well established as a beneficial therapy in a variety of medical applications. The scientific principle behind this technology is that an electric current passed through a coil will generate an electromagnetic field. These fields, in turn, have been shown to induce current within conductive materials placed within the field. When applied to the human body, pulsed electromagnetic stimulation has been found to be an effective method of stimulating nerves resting within the electromagnetic field. Building on recent data, which highlights the beneficial effects of invasive, needle-based electrostimulation (ES) of the posterior tibial nerve in individuals with OAB and UI, there is

strong evidence for the treatment of these ailments with the use of LoFIT. In particular, ES has been found to modulate bladder dysfunction through its action on the pudendal nerve and the sacral plexus which provides the major excitatory input to the bladder.

[0005] Current treatment options for OAB and UI are exercise and behavioral modifications, pharmacological therapies, surgical intervention, and neuromodulation. Although each of these treatment options targets the UI and OAB populations, each has severe limitations.

[0006] Exercise and behavioral modifications often require patients to adhere to stringent routines, including scheduled voiding, maintenance of a bladder diary, and intense exercise regimens. While this may be a viable option for a small group of highly dedicated individuals, its daily impact on one's life makes it an unattractive option for most individuals.

[0007] Pharmacological intervention is the most widely prescribed therapy for OAB and UI. Unfortunately, as with the ingestion of any chemical, patients are often subject to side effects from their drug therapy. This is especially detrimental in older and elderly patient populations where interaction with other prescribed medications can have adverse effects. Further, there is a high rate of dissatisfaction, approximately 30%, amongst individuals using pharmacological treatment.

[0008] Surgical intervention is an extremely invasive treatment and often results in the long-term, and in some cases permanent, requirement for catheterization. The high expense of these procedures, coupled with the negative impact the procedures have on the patients quality of life, make this an option only when all other treatment options have been exhausted.

[0009] Neuromodulation is another treatment alternative for OAB and UI patients. Sacral nerve stimulation (SNS) has shown itself to be an effective treatment option for those with OAB or UI. However, the procedure requires the permanent implantation of an electrical stimulation device in the patient. One estimate puts the cost at nearly \$14,000 with additional routine care costs of \$593 per patient per year. Additionally, SNS's risk of battery failure, implant infection, and electrode migration, lead to a high reoperation rate and make this procedure unattractive.

[0010] More recently, the introduction of a posterior tibial nerve stimulator, often referred to as SANS, has shown itself to be another neuromodulation alternative. Yet as is the case with other forms of neuromodulation, this system is invasive in its nature. It requires the insertion of a needle two inches into the patient's ankle region in order to stimulate the posterior tibial nerve.

As well, it requires a minimum of 12 sessions for initial treatment, with the possibility of additional sessions needed for maintenance. Despite its high cost and invasive nature, though, an abundance of published peer-reviewed clinical trials demonstrate the safety and efficacy of the SANS therapy.

REVIEW OF THE PRIOR ART

[0011] U.S. patent number 6,941,171 describes a method and system for treatment of incontinence, urgency, frequency, and/or pelvic pain includes implantation of electrodes on a lead or the discharge portion of a catheter adjacent the perineal nerve(s) or tissue(s) to be stimulated. Stimulation pulses, either electrical or drug infusion pulses, are supplied by a stimulator implanted remotely, and through the lead or catheter, which is tunneled subcutaneously between the stimulator and stimulation site. This device, while holding some therapeutic potential, is invasive in its delivery and requirement for implantation of device components.

[0012] U.S. patent number 5,984,854 describes a method for treating urinary incontinence which consists of delivering a train of current pulses through one or more magnetic stimulation coils to induce a train of magnetic flux pulses, which then induce an eddy current within the body, thereby to stimulate a group of pelvic floor muscles, the pudendal nerve, the external urethral sphincter, or the tibial nerve. While this device describes the employment of pulsed electromagnetic fields in the treatment of urinary incontinence, the application does not contemplate the use of any specific component to facilitate the placement of the magnetic coils over a targeted region of the body. That is, the application describes holding a coil over an intended region of the body, but does not contemplate the use of ergonomic wraps or other means for allowing an untrained user to apply the intended treatments. The application also does not call for the monitoring of the therapy using sensors to ensure that the nerve is actually being stimulated and does not provide for adjustability of the device by the healthcare provider or user in order to accommodate for commonly occurring physiologic and anatomic variations in nerve locations.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.